Advertisement

Banner Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

4-Antibody AG. (8/16/11). "Press Release: 4-Antibody AG Forms Collaboration with Human Genome Sciences". Basel.

Organisations Organisation 4-Antibody AG
  Group Agenus (Group)
  Organisation 2 Human Genome Sciences (HGSI) (Group)
  Today GlaxoSmithKline (GSK) (Group)
  Group GlaxoSmithKline (GSK) (Group)
Products Product MAb, human, fully
  Product 2 antibody technology
  Index term 2 4-Antibody–College Group: public relations, 201109 service existent by College Hill Life Sciences
Persons Person Burns, Robert F. (4-Antibody 201101– CEO before Affitech CEO before Celldex Therapeutics CEO)
  Person 2 Mayer, Robert (College Group 201205 Account Director College Hill Life Sciences Munich before Northbank Communications)
     


4-Antibody AG today announced the signing of a collaboration agreement with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies. Financial terms of the deal were not disclosed.

The collaboration with HGS is focused on 4-Antibody's proprietary high throughput in vitro Retrocyte Display® technology for rapid discovery of fully human antibodies against novel targets nominated by HGS. The Retrocyte Display® technology (Retroviral B lymphocyte Display) is a potent and fast tool for high quality therapeutic antibody discovery and optimization using a rapid flow cytometry approach. Full-length immunoglobulin antibody libraries are expressed in mammalian B-lineage cells, the cell designed by nature for optimal antibody display, resulting in 'better-behaved', fully human antibodies. This collaboration agreement, which initially involves two projects, is 4-Antibody's second such alliance with a pharmaceutical partner, the first being with Boehringer Ingelheim which commenced in early 2010.

Dr Robert Burns, 4-Antibody's CEO, said: "We're delighted to announce our second collaboration with an established pharmaceutical partner. Collaborations serve an important role in validating our Retrocyte Display® technology platform and we're delighted that HGS wanted to enter into this Multi-target collaboration with us. This adds an additional momentum to our other ongoing partnering activities."

- ends -

Further Information:

Dr Robert Burns
CEO
4-Antibody AG
t: +41-61-633-20-60
e: robert.burns@4-antibody.com

Dr Robert Mayer
Account Manager
College Hill
t: +49-89-5238-8030
e: robert.mayer@collegehill.com


About 4-Antibody AG

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating fulllength IgG format human antibody libraries expressed in mammalian B cells. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an inhouse pipeline of antibody drugs. The Company's lead development product is an anticytomegalovirus antibody drug. 4-Antibody is a private company with strong, commerciallyexperienced leadership located in Basel, Switzerland and Jena, Germany.

For more information please visit: www.4-antibody.com

*** 4-Antibody moves to new offices and labs***

Please note the new address and phone number of our Basel operation:
4-Antibody AG
Hochbergerstrasse 60C
CH-4057 Basel, Switzerland
Phone: +41-61-633-20-60


About Human Genome Sciences

Human Genome Sciences exists to place new therapies into the hands of those battling serious disease. For more information about HGS, please visit the Company's web site at www.hgsi.com .


4-Antibody AG
Hochbergerstrasse 60C
CH-4057 Basel, Switzerland
Phone: +41-61-633-2260
ir@4-antibody.com
www.4-antibody.com

   
Record changed: 2014-04-23

Advertisement

Banner EBD Group BIO Europe 2014 BEU Frankfurt November 600x60px

More documents for Agenus (Group)


To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

The Events Group Pharm Connect Congress 2015 Budapest February 600x60px




» top

Advertisements

Banner EBD Group BIO Europe 2013 BEU Frankfurt November 120x180px Highl Successful LC/MS Niche Player Is Looking for a Junior Partner 120x240px Banner LSBC Central European Life Science Investment Conference 2014 120x180px The Events Group Pharm Connect Congress 2015 Budapest February 120x180px Banner C5 Communications Life Sciences IP Summit 2014 Amsterdam 120x180px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Banner [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px